Aytu BioPharma (NASDAQ:AYTU) Earns Buy Rating from Analysts at Ascendiant Capital Markets

Ascendiant Capital Markets initiated coverage on shares of Aytu BioPharma (NASDAQ:AYTU) in a research note published on Monday morning, Marketbeat reports. The firm issued a buy rating and a $12.00 price objective on the stock.

Separately, Wall Street Zen raised shares of Aytu BioPharma to a “strong-buy” rating in a research report on Friday, June 27th.

Aytu BioPharma Price Performance

NASDAQ AYTU opened at $2.29 on Monday. The company has a market cap of $20.56 million, a price-to-earnings ratio of -3.18 and a beta of 0.13. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.03 and a quick ratio of 0.87. The stock’s fifty day moving average price is $1.76 and its 200 day moving average price is $1.52. Aytu BioPharma has a 1 year low of $0.95 and a 1 year high of $2.96.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Wednesday, May 14th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.37. Aytu BioPharma had a return on equity of 3.51% and a net margin of 2.37%. The business had revenue of $18.45 million for the quarter, compared to analyst estimates of $13.74 million.

Institutional Investors Weigh In On Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its stake in Aytu BioPharma Inc. (NASDAQ:AYTU) by 13.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 463,721 shares of the company’s stock after buying an additional 56,172 shares during the quarter. Stonepine Capital Management LLC owned approximately 7.52% of Aytu BioPharma worth $556,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.